Lazertinib Versus Gefitinib as First-line Treatment in EGFR-mutated Advanced NSCLC
1. Progression-free survival was longer in the lazertinib group vs the gefitinib group (20.6 months vs 9.7 months, with HR ...
Tag: EGFR tyrosine kinase inhibitors
Mobocertinib is a tolerable and possible treatment option for patients with EGFR exon 20 insertion mutated advanced non-small-cell lung cancer
1. Overall response rate was 28% and 35% in the platinum pretreated cohort (PPP) and 25% and 32% in the ...
Dacomitinib may be effective in EGFR-associated lung cancer
1. Patients with advanced EGFR-associated non-small-cell lung cancer treated with dacomitinib had increased progression-free survival as compared to those without ...
Radiation may have a role treating brain metastases from lung cancer
Image: PD 1. There was no difference in overall survival of patients with brain metastases from EGFR-mutant lung adenocarcinoma receiving ...
